Systemic sclerosis (SSc), also called scleroderma, is a chronic multisystem autoimmune connective tissue disease characterized by microvascular dysfunction, immune dysregulation, and progressive fibrosis of skin and internal organs. The hallmark triad links endothelial injury to aberrant immune signaling and fibroblast activation, culminating in excessive extracellular matrix deposition. Although disease heterogeneity is substantial—ranging from limited cutaneous forms to diffuse, rapidly progressive disease—most patients share overlapping mechanisms that drive organ risk, symptom burden, and long-term outcomes.
At the vascular level, early events include microvascular ischemia and abnormal angiogenesis. Endothelial dysfunction promotes vasoconstriction, platelet activation, capillary loss, and impaired tissue repair. Clinically, this contributes to Raynaud phenomenon, the most common presenting feature, and can evolve into digital ulcers, critical ischemia, and pulmonary vascular complications. Immune activation further sustains disease activity through cytokine networks and autoantibody production. Autoantibodies such as anti–topoisomerase I (Scl-70), anti–centromere, and others correlate with phenotypes and organ involvement, particularly interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH).
Fibrosis in SSc is driven by fibroblast-to-myofibroblast differentiation, transforming growth factor–beta–mediated profibrotic pathways, and dysregulated matrix remodeling. In the skin, collagen deposition thickens dermis and can restrict joint motion. In internal organs, similar fibrotic processes may affect the lungs, gastrointestinal tract, kidneys, heart, and kidneys. In ILD, progressive alveolar inflammation and scarring can lead to restrictive physiology and impaired gas exchange, often determining long-term survival. In addition, cardiac involvement—including myocardial fibrosis and conduction abnormalities—may produce arrhythmias, heart failure, and reduced exercise tolerance.
Skin manifestations reflect disease subtype and activity. Limited cutaneous SSc typically presents with skin thickening distal to elbows and knees, often accompanied by prominent vascular features and a higher frequency of PAH. Diffuse cutaneous SSc is associated with more extensive skin involvement, earlier internal organ involvement, and a greater risk of severe ILD and renal crisis. Edema and skin tightness may evolve into fixed induration, with telangiectasias, calcinosis, and in some cases ulceration. RA skin complications referenced in conference contexts highlight broader autoimmune dermatologic problems, but SSc is distinguished by the combination of microvascular injury and progressive fibrosis.
Pulmonary risk is central to SSc care. Two major phenotypes are ILD and PAH, and patients may develop either or both. ILD staging commonly uses high-resolution computed tomography patterns such as ground-glass opacities and fibrotic changes, paired with pulmonary function tests (PFTs). For PAH, echocardiography screens for right-heart strain, while confirmatory right-heart catheterization establishes diagnosis and guides therapy. Monitoring requires integrated assessment, because subclinical organ involvement can precede overt symptoms.
Treatment is phenotype-driven and aims to control immune activity, limit fibrosis progression, prevent vascular complications, and manage symptoms. Raynaud and digital ulcer prevention often rely on risk factor modification, smoking cessation, warmth, and vasodilator strategies. Calcium channel blockers are common for vasospasm; for refractory digital ulcers or ischemia, prostacyclin analogs, endothelin receptor antagonists, or other targeted approaches may be used depending on the clinical scenario.
For progressive ILD, immunomodulatory and antifibrotic strategies may be considered based on disease severity and trajectory. Glucocorticoid use is generally cautious and reserved for specific circumstances, because higher-dose exposure can increase adverse outcomes, including renal crisis risk. Immunosuppressive agents have historically been used in ILD, and contemporary evidence supports risk-adapted selection to balance efficacy with tolerability.
SSc renal crisis is a medical emergency characterized by abrupt onset of malignant hypertension and rapidly progressive renal impairment, often linked to vascular injury and activation of profibrotic pathways. Prompt recognition and aggressive blood pressure control—commonly with ACE inhibitors—are critical to prevent morbidity and mortality, even when renal function at presentation is severely reduced.
Because SSc is lifelong, structured monitoring is essential. Routine evaluations commonly include blood pressure and renal function tests, PFTs and symptom surveillance for ILD, echocardiography screening for PAH in appropriate patients, gastrointestinal assessment for reflux and dysmotility, and cardiovascular risk evaluation. Multidisciplinary care improves detection of complications, supports individualized treatment selection, and enhances patient-centered outcomes.
Finally, patient education and symptom management—pain control for ulcers, management of reflux, physical therapy to preserve range of motion, and psychosocial support—are integral parts of comprehensive SSc care. Ongoing clinical research continues to refine biomarkers, risk stratification, and mechanism-based therapies to slow fibrosis and reduce organ failure risk.
Source: Medscape
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
